Filing Details
- Accession Number:
- 0001870913-23-000003
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-08-16 19:07:03
- Reporting Period:
- 2023-08-14
- Accepted Time:
- 2023-08-16 19:07:03
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1023024 | Ani Pharmaceuticals Inc | ANIP | Pharmaceutical Preparations (2834) | 582301143 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1870913 | Muthusamy Shanmugam | C/O Ani Pharmaceuticals, Inc. 210 Main Street West Baudette MN 56623 | Head Of R&D, Coo-Novitium Ops | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2023-08-14 | 27,890 | $61.15 | 1,204,730 | No | 4 | S | Indirect | Held by Esjay LLC |
Common Stock | Disposition | 2023-08-15 | 22,110 | $61.60 | 1,182,620 | No | 4 | S | Indirect | Held by Esjay LLC |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | Held by Esjay LLC |
No | 4 | S | Indirect | Held by Esjay LLC |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 47,407 | Direct | |
Common Stock | 5,000 | Indirect | Held by SS Pharma LLC |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $60.12 to $62.58, inclusive.
- The reporting person holds voting and dispositive power over the shares held by Esjay LLC.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $60.81 to $62.59, inclusive.
- The Reporting Person holds voting and dispositive power over the shares held by SS Pharma LLC.